Skip to main content

Table 5 Comparison of drop-out rate mean values and reasons between NEONet database and published Real-life studies

From: Drop-out rate among patients treated with omalizumab for severe asthma: Literature review and real-life experience

  NEONet Real-life p-value
Drop-out 31.67 % 17.50 % 0.0000
Patient decision 48.57 % 35.01 % 0.0160
Lack of efficacy 25.71 % 23.53 % 0.3475
Adverse events 7.14 % 12.04 % 0.1176
Other causes 18.57 % 29.41 % 0.0318